Brown Health Dermatology Clinical Trial

LAVENDER

The LAVENDER trial will study the use of an injection to treat chronic and/or subacute cutaneous lupus. The study s a Phase 3 trial led by principal investigator Abrar Qureshi, MPH, MD and sponsored by AstraZeneca. Injections will be administered at study visits.

Brief Overview of Inclusion Criteria

This is only a brief overview and determination for this trial will be completed by participating in a formal screening. The screening will review all inclusion and exclusion criteria.

This study is for patients who:

  • are 18 to 70 years of age
  • have a confirmed diagnosis of chronic cutaneous lupus erythematosus (CLE)
  • have had an inadequate response or intolerant to antimalarial therapy.

The study is enrolling until April 2026. All eligible patients will be compensated for their time and travel to attend study visits.

More Information

For more information, contact Catherine Conley at [email protected] or by phone at 401-606-4697.

Dermatology